Matching articles for "opioid abuse"
In Brief: Over-the-Counter Narcan Nasal Spray
The Medical Letter on Drugs and Therapeutics • May 1, 2023; (Issue 1675)
The FDA has approved the over-the-counter (OTC)
sale of Narcan (Emergent), a nasal spray that delivers
4 mg of the opioid antagonist naloxone. Narcan nasal
spray has been available by prescription since...
The FDA has approved the over-the-counter (OTC)
sale of Narcan (Emergent), a nasal spray that delivers
4 mg of the opioid antagonist naloxone. Narcan nasal
spray has been available by prescription since 2015
for emergency treatment of opioid overdose. Generic
formulations of Narcan have also been approved; the
manufacturers of these products will be required to
switch them to OTC status and amend their labeling
accordingly. Kloxxado, an 8-mg naloxone nasal
spray, remains available only by prescription.
Nalmefene Returns for Reversal of Opioid Overdose
The Medical Letter on Drugs and Therapeutics • September 5, 2022; (Issue 1658)
The FDA has approved a generic injectable formulation
of the opioid antagonist nalmefene (Purdue) for the
management of known or suspected opioid overdose.
Revex, the reference product, was withdrawn from...
The FDA has approved a generic injectable formulation
of the opioid antagonist nalmefene (Purdue) for the
management of known or suspected opioid overdose.
Revex, the reference product, was withdrawn from the
market in 2008 for commercial reasons.
Zimhi - A Higher-Dose Injectable Naloxone for Opioid Overdose
The Medical Letter on Drugs and Therapeutics • April 18, 2022; (Issue 1648)
The FDA has approved a higher-dose injectable
formulation of the opioid antagonist naloxone
(Zimhi – Adamis) for emergency treatment of opioid
overdose. A single IM or SC injection of the new
formulation...
The FDA has approved a higher-dose injectable
formulation of the opioid antagonist naloxone
(Zimhi – Adamis) for emergency treatment of opioid
overdose. A single IM or SC injection of the new
formulation delivers 5 mg of naloxone; injectable
formulations that deliver 0.4 mg or 2 mg of the drug
have been available for years. Naloxone is also
available in intranasal formulations for the same
indication (see Table 1).
In Brief: Higher-Dose Naloxone Nasal Spray (Kloxxado) for Opioid Overdose
The Medical Letter on Drugs and Therapeutics • September 20, 2021; (Issue 1633)
The FDA has approved a higher-dose intranasal
naloxone formulation (Kloxxado – Hikma) for
emergency treatment of opioid overdose. A single
spray of the new formulation delivers 8 mg of
naloxone; a...
The FDA has approved a higher-dose intranasal
naloxone formulation (Kloxxado – Hikma) for
emergency treatment of opioid overdose. A single
spray of the new formulation delivers 8 mg of
naloxone; a formulation that delivers 4 mg per spray
(Narcan) was approved in 2015.